Director, Solid Tumor Lead, International Market Access and Pricing

About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on LinkedIn, Facebook , Instagram , X and YouTube.

The Director, Solid Tumor Lead, International Market Access and Pricing (IMAP), leads international access and pricing strategy for AbbVie’s solid tumor portfolio, including on-market assets such as Elahere and Teliso-V and near-term launches such as Temab-A in third-line colorectal cancer. Reporting to the VP Oncology IMAP, this leader translates clinical, payer, competitive, and policy insights into strategies that support reimbursement, patient access, and commercial success in priority international markets. Profile: Seasoned market access leader with deep pharmaceutical experience and a strong record of leading international access, pricing, and reimbursement strategies. Brings strategic judgment, business acumen, executive communication skills, and the ability to influence in a matrixed global organization. In this role, the leader is expected to convert broad portfolio strategy into asset-specific plans, cross-functional decisions, and market-level execution support.

Overall Lead integrated access strategy across the solid tumor portfolio, embedding payer, pricing, reimbursement, evidence, policy, clinical, medical, regulatory, commercial, area, and affiliate perspectives into asset, launch, and lifecycle plans. Own core international access deliverables, including value propositions, value dossiers, evidence priorities, payer materials, launch tools, and lifecycle plans. Translate clinical, HEOR, pricing, reimbursement, competitive, and payer insights into recommendations for development, evidence generation, commercialization, long-range planning, and business development. Advise headquarters and cross-functional partners on access conditions, evidence expectations, pricing dynamics, reimbursement risks, and patient access implications. Drive launch readiness and execution through cross-functional alignment and leadership of Value and Access Teams for priority assets. Lead direct and matrixed access, pricing, and HTA talent to coordinate, prioritize, and execute across solid tumor portfolio priorities. Represent access in asset, brand, leadership, and external forums, shaping policy, HTA, and reimbursement environments that support sustainable patient access. Manage projects, vendors, documentation, budgets, and compliance activities, prioritizing resources against high-impact access, evidence, and launch-readiness work. Asset-specific responsibilities: Lead access and pricing strategy for on-market assets, including Elahere lifecycle planning, payer value communication, evidence needs, affiliate support, and access optimization. Drive Teliso-V access strategy, including Brazil Phase 2 launch support, evaluation of additional near-term opportunities, and planning for the broader Phase 3-based launch strategy. Drive Temab-A access and pricing strategy as a near-term launch opportunity, with focus on third-line colorectal cancer and broader CRC, NSCLC, HNSCC, and PDAC development. Develop indication-specific access strategies for current and future multi-indication assets, accounting for clinical value, competition, sequencing, payer evidence needs, pricing, and market access pathways.

Required qualifications: 10+ years of progressive experience in market access, pricing and reimbursement, payer strategy, commercial strategy, HEOR, pricing policy, or